Viniegra M, Marchetti M, Losso M, Navigante A, Litovska S, Senderowicz A, Borghi L, Lebron J, Pujato D, Marrero H
Division of Neumonologia, Hospital de Clinicas, Buenos Aires, Argentina.
Cancer Chemother Pharmacol. 1990;26(3):227-31. doi: 10.1007/BF02897205.
Preclinical studies suggest that in addition to the well-known direct damage to the myocardium, anthracycline antineoplastic drugs exert toxic effects on the cardiovascular autonomic system as well. To investigate whether this phenomenon occurs in the clinic, we carried out noninvasive, widely used tests of cardiovascular autonomic physiology in 55 women with stage II or III breast cancer. In all, 31 were being treated with anthracycline-containing chemotherapy regimens, and 24 who were receiving CMF (cyclophosphamide, Methotrexate, and fluorouracil) served as controls. Of 279 tests conducted in anthracycline (A)-treated patients, 123 were abnormal, vs 54 of 216 tests carried out in 24 controls (44% vs 25%; P less than 0.005). Abnormal variations in heart rate on standing and in diastolic blood pressure during handgrip was found in 25 (81%) and 17 patients receiving A, vs 9 (37%; P less than 0.005) and 5 (21%; P less than 0.0001), respectively, in controls. The incidence of abnormal tests was significantly higher in A-treated patients greater than 60 years of age (41%) vs 67%; P less than 0.05). Radionuclide ventriculography was carried out in 19 patients who showed abnormal tests of cardiovascular autonomic function after greater than or equal to 6 courses of a-containing chemotherapy; only 1 of them had abnormal cardiac contractility (global hypokinesia), suggesting that abnormal tests of cardiovascular autonomic function may occur in the absence of a detectable deterioration in left ventricular ejection fraction. A large number of factors may alter cardiovascular autonomic function in cancer patients, including age, radiation therapy to the chest, and multidrug treatment. Even after correcting for the most obvious of these, chemotherapy with anthracyclines is associated with a significantly higher percentage of abnormal tests for cardiovascular autonomic function. Although indirect and semi-quantitative, our results are compatible with the idea of A-induced cardiac autonomic dysfunction.
临床前研究表明,除了众所周知的对心肌的直接损害外,蒽环类抗肿瘤药物对心血管自主神经系统也有毒性作用。为了研究这种现象在临床上是否会发生,我们对55名II期或III期乳腺癌女性患者进行了广泛使用的无创心血管自主神经生理学测试。其中,31名患者正在接受含蒽环类的化疗方案,24名接受CMF(环磷酰胺、甲氨蝶呤和氟尿嘧啶)治疗的患者作为对照。在接受蒽环类(A)治疗的患者中进行的279项测试中,123项异常,而在24名对照患者中进行的216项测试中有54项异常(44%对25%;P小于0.005)。接受A治疗的患者中,分别有25名(81%)和17名患者在站立时心率和握力时舒张压出现异常变化,而对照患者中分别为9名(37%;P小于0.005)和5名(21%;P小于0.0001)。60岁以上接受A治疗的患者中异常测试的发生率显著高于67%(41%对67%;P小于0.05)。对19名在接受≥6个疗程含A化疗后心血管自主神经功能测试异常的患者进行了放射性核素心室造影;其中只有1人心脏收缩功能异常(整体运动减弱),这表明在左心室射血分数未检测到恶化的情况下,心血管自主神经功能测试可能会出现异常。大量因素可能会改变癌症患者的心血管自主神经功能,包括年龄、胸部放疗和多药治疗。即使校正了其中最明显的因素后,蒽环类化疗与心血管自主神经功能异常测试的显著更高百分比相关。尽管我们的结果是间接的和半定量的,但与A诱导的心脏自主神经功能障碍的观点相符。